Bio-link Australia Pty. Ltd.


Please find below a list of selected recent news and press releases from Bio-Link, our clients and the industry. Please select a specific news list for each source from the buttons on the left hand side.

19th October 2017 – Heptares Therapeutics engages Bio-Link to identify clinical collaborators

Heptares Therapeutics, a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs) has engaged Bio-Link to identify clinical collaborators for clinical studies investigating the role of individual GPCRs in human health and there role in human pathogenesis.

17th July 2017 – Bio-Link’s Dr Lieven Huang Attending ‘Business of Regenerative Medicine’ in Toronto This Week

After winning a CCRM Australia grant, Bio-Link’s Dr Lieven Huang is attending the 2017 edition of ‘Business of Regenerative Medicine’ in Toronto, which is focused on the latest in commercialising regenerative medicine and stem cell therapies. The event is co-hosted by the Centre for Commercialization of Regenerative Medicine (CCRM) and the Rotman School of Management. More information about the event here.

10th July 2017 – First Dosing in a Phase 1b Combination Trial of the Dynamin Inhibitor Prochlorperazine and Anti-EGFR Monoclonal Antibody Cetuximab in Head and Neck Squamous Cell Carcinoma Patients.

The first two patients have been dosed in a phase Ib clinical trial at the Princess Alexandra Hospital (PAH, Brisbane, Australia), evaluating the efficacy of co-treatment of the anti-psychotic / anti-emetic drug prochlorperazine (Stemetil®) with anti-EGFR monoclonal antibody (mAb) cetuximab in head and neck squamous cell carcinoma (HNSCC) patients (HREC/16/QPAH/825). Prochlorperazine is a potent off-target inhibitor of the enzyme dynamin II. To learn more, please click here.

7th May 2017 – Oncology Venture – New APO010 multiple myeloma trial initiation

Oncology Venture, a precision oncology biopharmaceutical company and Bio-Link client, has recently announced important milestones in the development of its phase I/II immuno-oncology drug candidate APO010, granting of a key US patent for phase II ready drug candidate irofulven, and validation of its platform precision medicine technology, Drug Response Predictor™ (DRP™):

  • The first multiple myeloma patient was treated with APO010 in a phase 1/2 trial, by utilising the proprietary APO010 DRPTM companion diagnostic to select highly likely responders. Read more
  • Oncology Venture’s successful patent strategy is evident through a recently granted US patent covering the DRPTM and Irofulven. Irofulven is a potent anti-cancer drug candidate that will be tested in a focused phase 2 trial in likely patient responders with castration-resistant prostate cancer. Read more
  • The predictive power of the DRPTM was the topic of Oncology Venture’s recent ASCO poster presentation, demonstrating that it successfully predicts response to epirubicin, one of the most used breast cancer treatments. The DRPTM was significantly associated with Progression Free Survival (PFS) in a cohort of 135 metastatic breast cancer patients. Read more

oncology venture logo-1

8th May 2017 – Bio-Link Survey: Antibody(-like) Therapeutics in Australia


Bio-Link is engaged by a client to scout for Australian therapeutics programs with antibodies and antibody-like drugs. All stages of development are considered, both within academia (e.g. Garvan Institute’s Centre for Targeted Therapies) and industry (e.g. CSL). The scouting results are likely to be shared with the global pharma industry, which might boost commercial R&D activities in Australia. Names of research groups or companies can be submitted below.
Thanks for your input!

Organisation Details

Name of Research Groups and/or Companies:
Technology/Program Specifics:

Bio-Link Australia Pty Ltd ,
Suite 6/98 Glebe Point Road, Glebe, New South Wales, 2037
Level 2, Birdwood Offices, 19 Prospect Street, Box Hill, Victoria, 3128